Select Publications
Journal articles
2007, 'Can we deny patients expensive drugs? [2]', Australian Prescriber, 30, pp. 60
,2007, 'Expert comment [6]', Australian Prescriber, 30, pp. 61 - 62
,2007, 'Paracetamol comment', AUSTRALIAN PRESCRIBER, 30, pp. 61 - 62, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000434589000006&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2007, 'Utility of urine drug screening: A clinical audit', EMA - Emergency Medicine Australasia, 19, pp. 246 - 252, http://dx.doi.org/10.1111/j.1742-6723.2007.00922.x
,2007, 'The funding and use of high-cost medicines in Australia: The example of anti-rheumatic biological medicines', Australia and New Zealand Health Policy, 4, http://dx.doi.org/10.1186/1743-8462-4-2
,2007, 'Fenofibratewarfarin interaction [1]', Australian Prescriber, 30, pp. 32, http://dx.doi.org/10.18773/austprescr.2007.014
,2007, 'Pharmaceutical benefits scheme: Rapid change and impetus towards achieving QUM', Journal of Pharmacy Practice and Research, 37, pp. 4 - 6, http://dx.doi.org/10.1002/j.2055-2335.2007.tb00644.x
,2007, 'Targeted pharmacotherapy of evoked phenomena in neuropathic pain: A review of the current evidence', Pain Medicine, 8, pp. 48 - 64, http://dx.doi.org/10.1111/j.1526-4637.2007.00156.x
,2007, '639: Targeted pharmacotherapy of evoked phenomena in neuropathic pain', Journal of Clinical Neuroscience, 14, pp. 1031 - 1031, http://dx.doi.org/10.1016/j.jocn.2007.02.070
,2007, 'Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial', Lancet, 370, pp. 1638 - 1643
,2007, 'Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol', Clinical Pharmacokinetics, 46, pp. 623 - 644
,2007, 'Evaluating medicines: let`s use all the evidence', Medical Journal of Australia, 186, pp. 249 - 252
,2007, 'Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?', Internal Medicine Journal, 37, pp. 601 - 606, http://dx.doi.org/10.1111/j.1445-5994.2007.01396.x
,2007, 'Non-steroidal anti-inflammatory drugs in general practice: a decision-making dilemma', Medical Journal of Australia, 187, pp. 160 - 163
,2007, 'Open-label extension studies - Do they provide meaningful information on the safety of new drugs?', Drug Safety, 30, pp. 93 - 105
,2007, 'Patterns of analgesic and anti-inflammatory medicine use by Australian veterans', Internal Medicine Journal, 37, pp. 798 - 805
,2007, 'Prioritising drug and therapeutics committee (DTC) decisions: a national survey', Pharmacy World and Science, 29, pp. 90 - 96
,2007, 'Relationships between the adverse effects of drugs and genetic polymorphism in genes encoding drug metabolizing enzymes', British Journal of Clinical Pharmacology, 63, pp. 380 - 381
,2007, 'The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia', Australia and New Zealand Health Policy, 4
,2006, 'Response to expression of concern regarding VIGOR study.', N Engl J Med, 354, pp. 1196 - 1199, https://www.ncbi.nlm.nih.gov/pubmed/16544387
,2006, 'In reply [9]', Medical Journal of Australia, 184, pp. 44 - 45, http://dx.doi.org/10.5694/j.1326-5377.2006.tb00101.x
,2006, 'Can we deny patients expensive drugs?', Australian Prescriber, 29, pp. 146 - 148, http://dx.doi.org/10.18773/austprescr.2006.087
,2006, 'Access to high-cost medicines for the treatment of rheumatoid arthritis under Australia's pharmaceutical benefits scheme', Pharmacoepidemiology and Drug Safety, 15, pp. S213 - S213
,2006, 'Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target?', Internal Medicine Journal, 36, pp. 19 - 27, http://dx.doi.org/10.1111/j.1445-5994.2005.00992.x
,2006, 'Accessing health outcome data on high-cost medicines in Australia', Medical Journal of Australia, 184, pp. 411 - 413, http://dx.doi.org/10.5694/j.1326-5377.2006.tb00293.x
,2006, 'An integrated analysis of five double-blind, randomized controlled trials evaluating the safety and efficacy of a hyaluronan product for intra-articular injection in osteoarthritis of the kneel', Osteoarthritis and Cartilage, 14, pp. 859 - 866
,2006, 'Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity', Clinical Pharmacology and Therapeutics, 80, pp. 75 - 84
,2006, 'Giving and receiving of gifts between pharmaceutical companies and medical specialists in Australia', Internal Medicine Journal, 26, pp. 571 - 578
,2006, 'Pethidine in emergency departments: promoting evidence-based prescribing - Reply', Medical Journal of Australia, 184, pp. 44 - 45
,2006, 'Protocol for the Quick Clinical study - a randomised controlled trial to assess the impact of an online evidence retrieval system on decision-making in general practice', BMC Medical Informatics and Decision Making, 6
,2006, 'Response to expression of concern regarding VIGOR study', New England Journal of Medicine, 354, pp. 1196 - 1198
,2006, 'Utilisation of anti-rheumatic drugs in Australia: Impact of introducing high-cost biologics under the pharmaceutical benefits scheme', Pharmacoepidemiology and Drug Safety, 15, pp. S213 - S213
,2005, 'Perspectives on Drug and Therapeutics Committee policy implementation', Research in Social and Administrative Pharmacy, 1, pp. 526 - 545, http://dx.doi.org/10.1016/j.sapharm.2005.09.001
,2005, 'Evaluation of access to high-cost medicines in Australia using national claims data', VALUE IN HEALTH, 8, pp. A28 - A28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000233021700088&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2005, 'Access to medicines and high-quality therapeutics: Global responsibilities for clinical pharmacology', Medical Journal of Australia, 182, pp. 322 - 323, http://dx.doi.org/10.5694/j.1326-5377.2005.tb06728.x
,2005, 'The birth of ibuprofen', Australian Journal of Pharmacy, 86, pp. 84 - 85
,2005, 'Challenges and Progress in adverse event ascertainment and reporting in clinical trials', Journal of Rheumatology, 32, pp. 2030 - 2032
,2005, 'Cooperative partnerships or conflict-of-interest? A national survey of interaction between the pharmaceutical industry and medical organizations', Internal Medicine Journal, 35, pp. 206 - 210
,2005, 'Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects', British Journal of Clinical Pharmacology, 59, pp. 425 - 432
,2005, 'Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]', BMC Musculoskeletal Disorders, 6
,2005, 'Medical specialists and pharmaceutical industry-sponsored research: a survey of the Australian experience', Medical Journal of Australia, 182, pp. 557 - 560
,2005, 'Paracetamol should be first-line therapy in osteoarthritis', Medical Journal of Australia, 182, pp. 198 - 199
,2005, 'Pethidine in emergency departments: promoting evidence-based prescribing', Medical Journal of Australia, 183, pp. 129 - 133
,2005, 'Recent developments in targeting access to high cost medicines in Australia', Australia and New Zealand Health Policy, 2, pp. 1 - 8
,2005, 'Sample size is beside the point in policy development research', Australian and New Zealand Journal of Public Health, 29, pp. 583 - 583
,2005, 'Simultaneous determination of rofecoxib and celecoxib in human plasma by high-performance liquid chromatography', Journal of Chromatographic Science, 43, pp. 351 - 354
,2005, 'Standardized Assessment of adverse events in rheumatology clinical trials: Summary of the OMERACT 7 Drug Safety Module Update', Journal of Rheumatology, 32, pp. 2037 - 2041
,2005, 'Targeted access to high-cost medicines in Australia: Early analysis from a qualitative study', Value in Health, 8, pp. A28 - A28
,2005, 'Ties that bind - Multiple relationships between clinical researchers and the pharmaceutical industry', Archives of Internal Medicine, 165, pp. 2493 - 2496
,2005, 'Tolerability of paracetamol', Drug Safety, 28, pp. 227 - 240
,